Genmab A/S (NASDAQ:GMAB) Research Coverage Started at Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of Genmab A/S (NASDAQ:GMAB) in a research report report published on Tuesday, Marketbeat reports. The firm issued a buy rating and a $41.50 price target on the stock.

Other research analysts also recently issued research reports about the stock. Truist Financial reiterated a “buy” rating and set a $48.00 price target (down previously from $49.00) on shares of Genmab A/S in a research report on Thursday, November 6th. Wall Street Zen lowered shares of Genmab A/S from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Morgan Stanley began coverage on shares of Genmab A/S in a report on Monday. They issued an “equal weight” rating and a $34.00 price target for the company. Johnson Rice restated a “buy” rating on shares of Genmab A/S in a research report on Monday, October 27th. Finally, HC Wainwright reiterated a “buy” rating and issued a $39.00 price objective on shares of Genmab A/S in a research report on Wednesday, January 28th. Six research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Genmab A/S has a consensus rating of “Moderate Buy” and an average target price of $41.30.

Genmab A/S Stock Down 0.9%

NASDAQ GMAB opened at $28.90 on Tuesday. The stock’s 50 day simple moving average is $32.19 and its 200 day simple moving average is $29.87. Genmab A/S has a one year low of $17.24 and a one year high of $35.43. The firm has a market cap of $18.56 billion, a PE ratio of 18.65, a price-to-earnings-growth ratio of 17.12 and a beta of 0.90. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.02 and a quick ratio of 6.01.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Tuesday, February 17th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). The business had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.06 billion. Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%. As a group, sell-side analysts forecast that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. CIBC Private Wealth Group LLC increased its holdings in Genmab A/S by 291.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock valued at $25,000 after purchasing an additional 616 shares during the last quarter. Osaic Holdings Inc. increased its stake in shares of Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after acquiring an additional 440 shares during the last quarter. CWM LLC raised its position in shares of Genmab A/S by 50.5% in the 2nd quarter. CWM LLC now owns 1,797 shares of the company’s stock valued at $37,000 after acquiring an additional 603 shares during the period. NewEdge Advisors LLC boosted its stake in Genmab A/S by 1,229.0% during the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after acquiring an additional 1,143 shares during the last quarter. Finally, Brown Brothers Harriman & Co. grew its holdings in Genmab A/S by 143.4% during the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after purchasing an additional 780 shares during the period. 7.07% of the stock is currently owned by institutional investors.

Key Headlines Impacting Genmab A/S

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: HC Wainwright raised its price target to $40 and reiterated a “buy” rating, signaling meaningful upside vs. the current price and offering support for the stock. HC Wainwright raises target
• Positive Sentiment: Jefferies initiated coverage on Genmab, which typically increases visibility and trading interest from institutional investors. Jefferies Initiates Coverage
• Positive Sentiment: Morgan Stanley also began coverage, adding further analyst attention and potential buy-side interest. Morgan Stanley Begins Coverage
• Positive Sentiment: Consensus brokerage coverage across firms is a “Moderate Buy,” which may cushion downside and attract buyers at current levels. Consensus Moderate Buy
• Neutral Sentiment: Genmab summoned its Annual General Meeting for March 19, 2026 — routine corporate governance news without direct near-term earnings impact. AGM Notice
• Neutral Sentiment: A Benzinga roundup and other analyst summaries aggregate views from four analysts; useful for context but not a single catalyst. Analyst Outlook Roundup
• Neutral Sentiment: Short-interest reporting shows anomalous/zero values (data appears inconsistent), so it offers no clear read on immediate shorting pressure.
• Negative Sentiment: Q4 EPS missed estimates — reported ~$0.40 vs. ~$0.46 consensus — which is the primary near-term negative driver pressuring the stock despite revenue roughly meeting expectations. Q4 2025 Earnings Call Transcript

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.